Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
NCT03984448
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
- NCT03984448 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on NCT03984448 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03984448 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Double-Expressor Lymphoma; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Cyclophosphamide; Doxorubicin Hydrochloride; Etoposide; Lumbar Puncture; Positron Emission Tomography; Prednisone; Rituximab; Venetoclax; Vincristine Sulfate
- Arms
- Arm 1 (R-CHOP, DA-EPOCH-R) · Active comparator
- Arm 2 (R-CHOP, DA-EPOCH-R, venetoclax) · Experimental
- Enrollment
- 363 (estimated)
- Primary outcomes
- Progression-free survival (PFS) (phase II)
- PFS (phase III)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Oct 22, 2019
- Primary completion
- Aug 13, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03984448 · updated Oct 26, 2026
Publications
linked from the registry- Abramson JS, Geyer S, Giri S, Pederson L, Hudson A, Hsi ED, Mehta-Shah N, Reagan PM, Deming RL, Little RF, Gore S, Dinner SN, Vallurupalli A, Landsburg DJ, Kahl B, Friedberg JW, Bartlett NL, Leonard JP. Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial. Lancet Haematol. 2026 Sep;13(9):e626-e638. doi: 10.1016/S2352-3026(26)00191-2. PubMed 42660130
- Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol. 2021 Nov;8(11):e818-e827. doi: 10.1016/S2352-3026(21)00273-8. Epub 2021 Oct 8. PubMed 34634256